The Expression of Apolipoprotein D in Hepatocellular Carcinoma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : Apolipoprotein D (Apo D) has recently been identified as a novel tumor suppressor gene. Apo D may have a profound effect on the carcinogenesis and progression of hepatocellular carcinoma. This study was designed to evaluate the expression of Apo D in hepatocellular carcinoma and to investigate the relationship between the expression of Apo D and the clinicopathological characteristics and the patients’survival. Methods : An immunohistochemical study was performed on the tumors and tissues from 43 hepatocellular carcinoma (HCC) patients with controls to determine the expression of Apo D protein. Results : Our data showed that a higher expression of Apo D was seen in 10 of 43 cases (23.3%), while a lower and no expression of Apo D was observed in 28 of 43 cases (65.1%) and 5 of 43 cases (11.6%), respectively. A reduced expression of Apo D was correlated with the tumor stage (p = 0.037) and tumor size (p = 0.017). However, the patients’5-year survival was not associated with the expression of Apo D (p = 0.903). Conclusions : The results suggest that a reduced Apo D protein expression may play an important role in HCC progression as associated with the tumor stage and size, but it does not affect the survival of HCC patients.
Abstract
Background : Apolipoprotein D (Apo D) has recently been identified as a novel tumor suppressor gene. Apo D may have a profound effect on the carcinogenesis and progression of hepatocellular carcinoma. This study was designed to evaluate the expression of Apo D in hepatocellular carcinoma and to investigate the relationship between the expression of Apo D and the clinicopathological characteristics and the patients’survival. Methods : An immunohistochemical study was performed on the tumors and tissues from 43 hepatocellular carcinoma (HCC) patients with controls to determine the expression of Apo D protein. Results : Our data showed that a higher expression of Apo D was seen in 10 of 43 cases (23.3%), while a lower and no expression of Apo D was observed in 28 of 43 cases (65.1%) and 5 of 43 cases (11.6%), respectively. A reduced expression of Apo D was correlated with the tumor stage (p = 0.037) and tumor size (p = 0.017). However, the patients’5-year survival was not associated with the expression of Apo D (p = 0.903). Conclusions : The results suggest that a reduced Apo D protein expression may play an important role in HCC progression as associated with the tumor stage and size, but it does not affect the survival of HCC patients.
참고문헌 (14)
- Parkin DM, "Global cancer statistics,2002", CA Cancer J Clin, 55, pp.74~108 (2005)
- Bosch FX, "Epidemiology of primary liver cancer", Semin Liver Dis, 19, pp.271~285 (1999)
- Park JH, "Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells", Cancer Res, 65, pp.2804~2814 (2005)
- Watanabe T, "Identification of immunoglobulin superfamily 11(IGSF11)as a novel target for cancer immuno therapy of gastrointestinal and hepatocellular carcinomas", Cancer Sci, 96, pp.498~506 (2005)
- McConathy WJ, "Isolation and partial characterization of apolipoprotein D:a new protein moiety of the human plasma lipoprotein system", FEBS Lett, 37, pp.178~182 (1973)
- Francone OL, "Distribution and functions of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins.Evidence for a functional unit containing these activities together with apolipoproteins A-I and D that catalyzes the esterification and transfer of cell-derived cholesterol", J Biol Chem, 264, pp.7066~7072 (1989)
- Lopez-Boado YS, "Apolipoprotein D gene induction by retinoic acid is concomitant with growth arrest and cell differentiation in human breast cancer cells", J Biol Chem, 269, pp.26871~6878 (1994)
- Díez-Itza I, "Expression and prognostic significance of apolipoprotein D in breast cancer", Am J Pathol, 144, pp.310~320 (1994)
- Vazquez J, "Expression and clinical significance of apolipoprotein D in epithelial ovarian carcinomas", Gynecol Oncol, 76, pp.340~347 (2000)
- Hall RE, "Apolipoprotein-D:a novel cellular marker for HGPIN and prostate cancer", Prostate, 58, pp.103~108 (2004)
- Alexander H, "Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid", Clin Cancer Res, 10, pp.7500~7510 (2004)
- Utsunomiya T, "Clinicopathologic and prognostic values of apolipoprotein D alterations in hepatocellular carcinoma", Int J Cancer, 116, pp.105~109 (2005)
- Vizoso FJ, "Liver expression of steroid hormones and Apolipoprotein D receptors in hepatocellular carcinoma", World J Gastroenterol, 13, pp.3221~3227 (2007)
- Schoppmann SF, "Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer", Int J Cancer, 104, pp.677~682 (2003)